September 14, 2008Open Access

Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma

Key Points

Key points are not available for this paper at this time.

Abstract

Based on our data, KRAS mutations are not rare among never smokers with lung adenocarcinoma and such patients have a distinct KRAS mutation profile. The etiologic and biological heterogeneity of KRAS mutant lung adenocarcinomas is worthy of further study.

AIに質問

Bookmark

View Full Paper

Cite This Study

Riely et al. (Sun,) studied this question.

synapsesocial.com/papers/69de6ce4bf539e22705588db https://doi.org/https://doi.org/10.1158/1078-0432.ccr-08-0646

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Prospective trial with preoperative gefitinib to correlate lung cancer response with EGFR exon 19 and 21 mutations and to select patients for adjuvant therapy2006 · 17 citations
2Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer2005 · 1,832 citations
3KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib2005 · 1,525 citations
4First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations2008 · 835 citations
5Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer2004 · 1,231 citations

AIに質問

Bookmark

View Full Paper